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A B S T R A C T
We systematically reviewed the ﬁles of 51 infants presenting with infantile spasms and hypsarrhythmia
in order to study the initial treatment strategies and the long term outcome. 80% of the infants were
classiﬁed as symptomatic. In the nine participating centres, different treatment protocols were used, but
the largemajority of the children received vigabatrin as ﬁrst line treatment. Second line options included
hormonal treatment, topiramate and valproate. The time to reach cessation of infantile spasms was
signiﬁcantly shorter in the cryptogenic group than in the symptomatic group (50% at 13 days versus 66
days respectively) and was irrespective of the treatment used. The late follow up data (>2 years) showed
that 60% of the children had epilepsy and that 75% of the children had a delay in their psychomotor
development. Again, outcome in the cryptogenic group was better than in the symptomatic group, but
also in the cryptogenic group, 50% of the children had a clear developmental delay, even if spasms were
controlled early in the course of the disease. Our retrospective study illustrates that not only the
underlying brain dysfunction is the major determinant for later outcome in infantile spasms
(symptomatic group) but also even a short period of infantile spasms can be responsible for later
developmental delay (cryptogenic group).
 2010 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
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Infantile spasms (or epileptic spasms, see new ILAE deﬁnition1)
remain one of themost catastrophic seizure types in childhood and
are usually indicative of a true epileptic encephalopathy, especially
when these seizures are associated with hypsarrhythmia on the
EEG. Children presenting with infantile spasms and hypsarrhyth-
mia have a high risk of developing cognitive deterioration (the so
called West syndrome).2,3 In contrast with other epilepsy
syndromes, early and aggressive anti-epileptic treatment is
warranted, since an early control of the infantile spasms is
associated with a higher chance of a normal cognitive outcome.3–5
In this respect, both seizure control and long term cognitive
outcome have to be considered as major outcome parameters in
any study on infantile spasms.6,7* Corresponding author. Tel.: +32 16 34 38 45; fax: +32 16 34 38 42.
E-mail address: lieven.lagae@uzleuven.be (L. Lagae).
1059-1311/$ – see front matter  2010 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2010.01.008Different treatment modalities have been studied in infantile
spasms, and several lines of evidence point to hormonal treatment
(ACTH, oral steroids) or vigabatrin as ﬁrst line options in the
treatment of infantile spasms.2,8,9 In the recently published
prospective United Kingdom Infantile Spasms Study, hormonal
treatment was shown to be superior in the early outcome
measurements at 13–14 days, but the difference did disappear
at 14 months.10,11 At the cognitive level, developmental outcome
was better after initial control with hormonal therapy in those
without an identiﬁed underlying etiology. It should be noted that
children with tuberous sclerosis were excluded in this study,
because in many European centres vigabatrin has already become
the ﬁrst line approach. In an earlier study by Vigevano and Cilio12
also comparing ACTH versus vigabatrin, similar effect estimates
were obtained.
In other smaller studies, older and newer anti-epileptic drugs
have been advocated as potential treatments in infantile spasms;
valproate,13 levetiracetam,14 nitrazepam,13 sulthiame,15 zonisa-
mide,16 pyridoxine15 and topiramate.17–20vier Ltd. All rights reserved.
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Neurology and the Child Neurology Society, nine prospective
studies were analyzed, but an optimal treatment option could not
be recommended.21 It was concluded that ACTH is probably
effective and that vigabatrin is possibly effective in the short term
treatment of infantile spasms. This absence of strong evidence was
further underscored in a recent Cochrane review. The available
studies do however show that the resolution of spasms is faster
with ACTH than with vigabatrin.9 Concerning long term develop-
mental outcome, evidence is even weaker and multiple factors to
explain normal or abnormal developmental outcome have to be
taken into account. The underlying brain etiology certainly is a
strong determining factor. In the symptomatic group, with an
identiﬁable cause for the infantile spasms, outcome seems always
worse than in the cryptogenic group,7–10 in which despite a
thorough diagnostic work-up, no cause for the spasms is found.
With the availability of different hormonal products and
different anti-epileptic drugs (vigabatrin, valproate, topiramate,
zonisamide, benzodiazepines, sulthiame), and the lack of convinc-
ing guidelines with clear treatment preferences, the treating
physician is left with different treatment possibilities.22,23 In the
best case, each centre develops a strict treatment protocol based on
personal experience, existing guidelines, practice parameters and
availability of anti-epileptic drugs.
We studied the efﬁcacy of the different treatment protocols that
are currently being used in nine large neuropediatric units
(including six university centres) in Belgium. Apart from zonisa-
mide, all major anti-epileptic drugs are available in Belgium,
although not all of them are registered for use in this young age
group. We were especially interested in the number of children
becoming seizure free in the early course of the disease, in the
developmental outcome, and in the relationship between under-
lying cause (symptomatic versus cryptogenic groups) and efﬁcacy
(=epilepsy and cognitive outcome).
2. Methodology
This is a standardized retrospective ﬁle review of all new cases
with infantile spasms presenting between 1 January 2002 and 31
December 2005 in one of the nine participating centres in Belgium.
In all participating centres, qualiﬁed pediatric neurologists were
responsible for the initial treatment and follow up of the children.
Since it was our belief that the large majority of the children
presenting with infantile spasms were referred to one of these
centres, our study sample should reﬂect the clinical reality in
Belgium concerning treatment and follow up of children with
infantile spasms.
Formal inclusion criteria for the study were:
- presentation with infantile spasms between 1 January 2002 and
31 December 2005, and for which treatment was started
between 1 January 2002 and 31 December 2005;
- hypsarrhythmia or modiﬁed hypsarrhythmia on the EEG before
the start of the treatment;
- age at onset of the infantile spasms between 1month and 2 years
of age;
- follow up period of at least 18 months.
From each patient ﬁle, the following data were retrieved:
- Reported age at onset of the infantile spasms.
- Pediatric and neurological diagnosis.
- Apparent delay between presentation of the spasms and start
treatment.
- Presence and type of seizures before the diagnosis of infantile
spasms.- Age at start treatment of the infantile spasms.
- Initial treatment for infantile spasms.
- Ages at subsequent follow up visits.
- Changes of treatment throughout the follow up period.
- Efﬁcacy of the different treatments: seizure frequency at each
follow up visit. Only presence or absence of infantile spasms was
determined. More speciﬁcally, three categories were used:
positive response, relapse, or persistent. A positive response
indicates that the child was spasm free for more than 1 week at
the time of the visit. Seizure frequency was assessed by seizure
diaries.
- Developmental outcome at the long term follow up visit (see
below).
For each individual child, we selected four visits in the ‘early
follow up period’. Visit 1 was deﬁned as the visit when the
treatment for infantile spasms was started. Visit 2 (median: 15
days, range: 9–42 days) was a visit occurring within 4–5 weeks
after the start of the treatment. Visit 3 (median: 41 days, range: 25–
70 days) and visit 4 (median: 110 days, range: 66–212 days) were
regular follow up visits scheduledwithin the ﬁrst 3–4months after
start of the treatment. The majority of the children had indeed
more than four visits in the ﬁrst 4 months, but only those visits
with sufﬁcient clinical data on ﬁle were used for analysis. Although
the variability (between centres and within centres) of the follow
up visits, this methodology allowed us to construct Kaplan–Meier
plots to see the effect of treatment during this early follow up
period.
Visit 5 was deﬁned as the ‘long term follow up visit’, at least 18
months after the start of the treatment for infantile spasms. Visit 5
took place between 2.07 years and 2.55 years (median: 2.38 years).
At this last visit, an assessment of the development was made.
To be valid, a written comment on the development and the
instruments used to assess the development had to be found in the
patient ﬁles. As different centres used different semi quantitative
scales to assess cognitive and developmental outcome, we
dichotomized this outcome parameter as normal or abnormal.
‘Abnormal’ refers to a signiﬁcant delay in one or more of the
different developmental ﬁelds.
For further analysis, each patient was classiﬁed into one of the
following groups, following the proposed ILAE and West Delphi
classiﬁcation Schemes1–6:
- Cryptogenic group: no identiﬁable cause found, normal devel-
opment at the onset of the spasms, 1.5T MRI normal, pediatric
and neurological examination normal, genetic and metabolic
screening when applicable: no abnormalities found (‘no proven
etiology’).
- Symptomatic group: a clear cause for the spasms was shown or
suspected.
It should be noted that this classiﬁcation for each childwas only
made at the end of the study, sometimes after a long lasting
diagnostic work-up.
This protocol was discussed with the different principal
investigators of the different participating centres and was
approved by the ethical committee of the leading centre (Leuven
UZ).
3. Results
Overall, 51 children could be included in this study. In view of
the yearly number of live births in Belgium (about 100,000) and the
estimated incidence of 2–4 new cases per 10,000 living births,24
our study sample roughly covers 50% of the expected cases in these
4 recruiting years.
Table 1
Number of patients per diagnostic group.
 Cryptogenic 10
 Symptomatic 30
– Perinatal problems, HIE 15
– Tuberous sclerosis 3
– Chromosomal 5




– Only abnormal development before spasms start 11
Total 51
Table 2
Total group: prescribed treatments per visit.
Visit 1 2 3 4
Steroids/ACTH 1 5 8 8
VGB 34 41 38 27
TOP 4 14 21 23
VPA 12 17 19 15
PB 1 1 1 1
BZP 0 1 5 5
PYR 3 1 1 1
Other AEDs 0 2 3 4
Table 2A
Symptomatic group: prescribed treatments per visit.
Visit 1 2 3 4
Steroids/ACTH 0 3 5 7
VGB 27 32 33 26
TOP 4 12 17 21
VPA 11 14 16 13
Table 2B
Cryptogenic group: prescribed treatments per visit.
Visit 1 2 3 4
Steroids/ACTH 1 2 3 1
VGB 7 9 5 1
TOP 0 2 4 2
VPA 1 3 3 2
L. Lagae et al. / Seizure 19 (2010) 159–164 161Table 1 shows that the largemajority of the children (n = 41/51,
80%) presenting with infantile spasms were classiﬁed in the
symptomatic group. Of those, 11 presented with a developmental
delay at the onset of the spasms, but no deﬁnite underlying
diagnosis could be made, even at the end of the early follow up
period of 3–4 months. In the other 30 children a variety of causes
for the infantile spasms were found. The largest group consisted of
childrenwith perinatal hypoxic-ischemic problems. Three children
suffered from tuberous sclerosis.
Despite extensive work-up no diagnosis could be found in 10
children with a normal development at the onset of the spasms:
these were considered as cryptogenic.
The onset of the infantile spasms was not signiﬁcantly different
in both groups. The median age at onset in the symptomatic group
was 6.2months (IQR 4.4–9.3months) and in the cryptogenic group
6.5 months (IQR 6.2–8.6 months). Interestingly, 41% (17/41) of the
children in the symptomatic groupwere already knownwith other
seizures before the onset of the infantile spasms. In 12 of these 17
children, these pre-existing seizures were classiﬁed as generalized
seizures. Only in one child in the cryptogenic group, a single short
lasting generalized febrile seizure had occurred before the start of
the infantile spasms.
We also assessed the delay between the onset of the infantile
spasms and the start of the treatment (visit 1). This period reﬂects
the time needed to recognize the infantile spasms but also
included the time to organise and perform a diagnostic EEG as well
as the time to refer the child to one of the specialized clinics.
Overall, this delay period was very short with a mean delay of 6
days, illustrating a very fast recognition of the spasms. The longest
delay was 155 days. This particular child was known with
myoclonic seizures. After 5 months the character of the seizures
changed and appeared in clusters, and the EEG now showed
(modiﬁed) hypsarrhythmia. The ‘delay’ between onset of infantile
spasms and start of treatment at visit 1 was longer in the
symptomatic group (mean: 7 days, range: 0–155 days) than in the
cryptogenic group (mean: 2 days, range: 0–19 days).
3.1. Initial treatment (Table 2)
Looking at the medications that were prescribed at visit 1 and
during the early follow up period, it is obvious that there is no
uniform treatment protocol (Table 2). Nevertheless, 34/51 children
got vigabatrin as initial therapy. Only one child got hormonal
therapy (ACTH) as ﬁrst line treatment. As can be calculated, the
sum of all the treatment options at visit 1 exceeds 51, which
indicates that some of the children were already on anti-epileptic
medication before the start of this study. This was the case for four
children: three were already on valproate and one was on
pyridoxine before the actual start of the speciﬁc treatment for
infantile spasms. This means that in nine children valproate was
prescribed as ﬁrst drug for infantile spasms. Topiramate wasconsidered ﬁrst line drug in four children. There were only minor
differences between the two patient groups, with ﬁrst line use of
vigabatrin in the cryptogenic group (7/10, 70%) and in the
symptomatic group (27/41, 66%) being very similar. For the other
children in the symptomatic group valproate (n = 11) and
topiramate (n = 4) were prescribed as ﬁrst line treatment. In
contrast, only one child in the cryptogenic group received
valproate as ﬁrst line treatment (Tables 2A and 2B).
During the following visits, the variability becomes even more
striking. At visit 2, the largemajority (41/51, 80%) childrenwere on
vigabatrin. Throughout the follow up, more children were put on
steroids/ACTH, on valproate and on topiramate. Also, the use of
benzodiazepines (clobazam, clonazepam and nitrazepam) became
more prevalent. The other two anti-epileptic drugs that were
prescribed in a minority of the children, in this early follow up
period were levetiracetam and lamotrigine.
3.2. Efﬁcacy
Because of the large variability of the scheduled follow up visits
in the early course of the disease, efﬁcacy of the given treatment for
infantile spasmswas ﬁrst formerly assessed at visit 4 (median: 110
days, range: 66–212 days). Overall, 69% were free of infantile
spasms at visit 4. In the cryptogenic group, 9/10 children were free
of infantile spasms (versus 27/41; 66% in the symptomatic group).
Two of the children (both in the symptomatic group) who
presented at visit 4 with infantile spasms, were spasm free at
visit 2 or 3, but had a relapse (Fig. 1).
Fig. 2 shows the cumulative probability of becoming spasm free
(Kaplan–Meier analysis). Overall, 50% of the children reached
seizure freedom by 45 days. Here, major differences were found
between the cryptogenic and symptomatic groups. In the
cryptogenic group the 50% level was reached at 13 days, and at
66 days for the symptomatic group. Actually, 4/10 children in the
Fig. 1. Outcome (infantile spasms) at visit 4.
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start of the treatment. This signiﬁcant ﬁnding is also illustrated by
looking at the ‘positive response at 1 month’, which is only 14% in
the symptomatic group and 90% in the cryptogenic group. The
ﬁgure further shows that after 120 days, chances of becoming
seizure free became very low.
We also analyzed what medication the children were taking at
the time of the control of the infantile spasms, whenever thisFig. 2. Efﬁcacy cumulative probability of becoming infantile spasm free.happened during the followup. In the symptomatic group, 60%was
on vigabatrin, in monotherapy (19%) or in combination therapy
with valproate or topiramate. In the cryptogenic group, eight of the
nine children were on vigabatrin and 2/9 on ACTH (one together
with vigabatrin).
3.3. Long term efﬁcacy and effect on development
Long term outcome was assessed at visit 5, which was done
after a minimal follow up of 2 years (median: 2.38 years, range:
2.07–2.55). One child was lost to follow up and two children died
during the study period (one because of septic shock during ACTH
treatment and one due to an underlying mitochondrial encepha-
lopathy; both in the symptomatic group).
In contrast with the outcome measures in the early follow up
phase, we focused on the presence or absence of epilepsy (and thus
not only on the presence or absence of infantile spasms) and on the
development. 40/48 children were still on anti-epileptic treat-
ment. Different anti-epileptic drug schedules were used. The
majority of the children were on VPA (n = 23) in monotherapy
(n = 10) or in combination with other AEDs. Most commonly used
were topiramate (n = 15), levetiracetam (n = 5), or vigabatrin. 10
children were still on vigabatrin at visit 5. Other AEDs used at visit
were phenobarbital, lamotrigine and sulthiame. Benzodiazepines
were being used in six children at visit 5. Overall, 60% of the study
group was seizure free (Fig. 3). As expected, the epilepsy outcome
in the cryptogenic group was excellent with 9/10 children
completely seizure free. On the other hand, in the symptomatic
group, only 54% of the children were seizure free. In those children
without epilepsy control, 44% had generalized seizures.
The presence of infantile spasms at visit 4 (last visit early follow
up) was highly predictive for epilepsy outcome at the long term
follow up visit. 84% of the children with infantile spasms at visit 4,
had epileptic seizures (epileptic spasms and/or other seizure
types) at long term follow up. In contrast, 77% of the children
without infantile spasms at visit 4 were completely seizure free at
long term follow up.
The results on development were less straightforward (Fig. 4).
As mentioned in Section 2, we considered a developmental delay
only when a description of the deﬁcit was detailed in the patient
ﬁle. On the other hand a child was considered normal, when this
was explicitly stated in the patient ﬁle. Overall, 75% of the children
at long term follow up did show a developmental delay. In the
symptomatic group, this percentage was as high as 80%. However
in the cryptogenic group, with 90% of the children being spasm free
at visit 4 and epilepsy free at the long term visit, 5/10 (50%) showed
a developmental delay. One child in this group was never infantileFig. 3. Long term outcome: epilepsy.
Fig. 4. Long term outcome: development.
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follow up. The four other children in the cryptogenic group with
developmental delay had an early control of the infantile spasms
and did not develop other seizure types, but had extra speech
therapy (n = 2) for language delay or/and physiotherapy for motor
delay at Kindergarten-age (n = 3). In two of these ﬁve children, an
autistic spectrum disorder was suspected.
4. Discussion
Our retrospective analysis of the treatment practices for
infantile spasms in Belgium between 2002 and 2005, largely
conﬁrms the data that are available in the literature, and certainly
illustrates the clinical reality beyond the world of randomized
controlled trials. Because of its retrospective nature, we should be
very cautious not to over-interpret our ﬁndings. However, as
recognized by many authors, there is deﬁnitively a need for more
data that show how and what treatment options are offered to
children presenting with infantile spasms in clinical reality.
We were surprised by the relatively small number of children
included in the study. The major Belgian neuropediatric centres
participated in the study, but only about 50% of the possible
subjects were included. This was partly due to the study
requirements, but it also indicates that some infants are being
followed at smaller non-university centres. Probably, this indicates
an inclusion bias with the more severe cases referred to the larger
participating centres.
We were conﬁdent that the necessary diagnostic studies were
performed in all subjects, and our distinction between the
symptomatic and cryptogenic group was made only at the end
of the study. This explains whywe could classify as much as 80% in
the symptomatic group, which is larger than for instance in the
UKISS study, where the classiﬁcation was made earlier in the
study.10,11 There is an ongoing discussion in the literature about
the classiﬁcation in idiopathic, cryptogenic and symptomatic
groups.6 We pragmatically followed the ILAE guidelines with two
groups: a symptomatic and cryptogenic group.1
A ﬁrst major difference with the current knowledge was the
very short delay between onset of infantile spasms and the start of
the treatment. This treatment delay was very short (2 days) in the
cryptogenic group and also shorter in the symptomatic group than
what is known in the literature. It points to an adequate
recognition of the disease by pediatricians and (pediatric)
neurologists in Belgium, and to the fast referral system. Some
papers have shown that the delay between the onset of the spasms
and the start of the treatment partly explains the long term
developmental outcome.4,25 As this period is shorter in our study,
this factor will play a lesser role to explain the (high frequency of
the) possible developmental delay. Also, the presenting phenotype
and hence the classiﬁcation into cryptogenic or symptomatic willnot be obscured by a long lasting pre-treatment period with
infantile spasms.
It is obvious that there is a need for a more uniform treatment
protocol in Belgium. Even within the single centres, we could not
always ﬁnd a strict protocol. However, our study shows that
vigabatrin certainly is the ﬁrst line treatment choice. Overall 42 out
51 children were offered vigabatrin as ﬁrst or second treatment
option. To our surprise, only a minority of the children were put on
steroids or ACTH in this cohort. We checked the dosages that were
used. In the small group, daily dosages were all <50 IU/day (given
for an average of 8 days). In the symptomatic group but also in the
cryptogenic group, valproate and topiramate were also frequently
used. In a recent comparable survey in Japan, valproate, ACTH,
zonisamide and pyridoxine were the drugs of choice with
pyridoxine as a major ﬁrst line.26 Only in four children in our
study, pyridoxine was tried.
Of course, cessation of spasms is the most important outcome
measure in the early phases of the disease, as it is generally
believed that the earlier the control of the spasms, the better the
developmental outcome can be. Our data allow us to study the
cumulative probability of becoming infantile spasm free. We also
determined outcome at the end of the early follow up period (visit
4). In contrast with the controlled studies, but perhaps in
concordance with the clinical reality, we did ﬁnd that it took
longer than expected to get the children spasm free. Especially in
the symptomatic group, it was not infrequent to needmore than 40
days before spasms could be controlled. This probably also
explains the many changes in the treatment schedules during
the follow up, aiming to stop the spasms as fast as possible.
On the other hand, looking at the number of children being
spasm free at visit 4, we ﬁnd a somewhat higher proportion of
children being seizure free than in the UKISS or the Vigevano
study.11,12 Here, perhaps the largest difference between the
cryptogenic and symptomatic group was found. In the cryptogenic
group, control occurred very early in 90% of the children, while it
took signiﬁcantly longer in the symptomatic group to get a smaller
percentage spasm free. As vigabatrin was used equally frequent in
both groups, this temporal difference in control is probably not due
to the treatment started (as shown in the Cochrane review9), but
rather to the underlying presence or absence of a brain
dysfunction.
The incidence of epilepsy at the long term follow up showed
that 60% of the children had no seizures at this last visit, but all
were still under medication. Again the percentage of seizures was
signiﬁcantly higher in the symptomatic group than in the
cryptogenic group. The number of children with partial seizures
was comparable to what was found in other long term follow up
studies3 and reﬂects the focal brain lesions in the symptomatic
group. Although we did not study the medications taken at that
long term visit systematically, we did not observe a major shift to
for instance AEDs with a narrower spectrum proﬁle (especially
carbamazepine, oxcarbazepine).
Our developmental outcome data do underscore the impor-
tance of ﬁnding the possible brain dysfunction: in the symptomatic
group, 80% of the children remained developmentally delayed.
Although counter-intuitive for the parents, not ﬁnding a cause for
the infantile spasms should be considered as a positive prospective
factor concerning epilepsy and developmental outcome. However,
we also found a high incidence of developmental problems in the
cryptogenic group. These were children without a pre-existing
developmental abnormality or neurological abnormalities, and
with a 90% chance of becoming infantile spasms free early in the
follow up, but still 50% had a developmental problem at the long
term follow up period. Of course, it is possible that an underlying
diagnosis was missed in these children. The diagnostic examina-
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these children however.
This difference in outcome could also be explained by the
treatment choice. In our population, the largemajority was treated
with vigabatrin. In recent studies, it was clearly shown that initial
ACTH treatment might give a better developmental outcome
compared to vigabatrin.7,10
Overall, our retrospective survey actually indicates that
comparable outcome measures were obtained with the use of
vigabatrin early in the course of the disease, and with patient-
driven changes in the drug treatment. ACTH or steroids were used
as second lines, together with topiramate and vigabatrin. Although
early response appears later than expected, the ultimate outcome
regarding development and epilepsy is very comparable to the
ones reached with more prospective and controlled studies. A
major conclusion is that the ﬁnding of a cause for the infantile
spasm is related with a worse outcome.
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